Kiniksa Pharmaceuticals International (KNSA) Operating Margin (2021 - 2026)

Kiniksa Pharmaceuticals International's Operating Margin history runs 6 years deep, the most recent figure standing at 13.66% for Q1 2026.

• Quarterly Operating Margin rose 403.0% year-over-year to 13.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.36% (up 1565.0% YoY) and the FY2025 annual result came in at 11.4%, up 2217.0% from the prior year.
• Operating Margin was 13.66% for Q1 2026 at Kiniksa Pharmaceuticals International, up from 9.78% in the prior quarter.
• Across five years, Operating Margin topped out at 46.82% in Q3 2022 and bottomed at 72.44% in Q1 2022.
• A 5-year average of 7.72% and a median of 4.08% in 2022 frame the typical range for Operating Margin.
• Annual changes were most pronounced in 2022 — Operating Margin soared 45461 bps — and 2023, when it sank 6312 bps.
• Kiniksa Pharmaceuticals International's Operating Margin stood at 4.08% in 2022, then jumped by 102 bps to 0.1% in 2023, then sank by 16315 bps to 15.75% in 2024, then soared by 162 bps to 9.78% in 2025, then surged by 40 bps to 13.66% in 2026.
• Business Quant data shows KNSA's Operating Margin at 13.66% in Q1 2026, 9.78% in Q4 2025, and 13.28% in Q3 2025.